Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Goldman Sachs Initiates Coverage On Vor Biopharma with Neutral Rating, Announces Price Target of $6
Goldman Sachs analyst Andrea Tan initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Neutral rating and announces Price Target of $6.
Akron Bioproducts, Vor Bio To Collaborate On The Development And CGMP Manufacture Of Nucleases
Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop
Vor Biopharma Q4 EPS $(0.49)
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.49) per share.
